200 related articles for article (PubMed ID: 18577988)
1. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients.
Cappuzzo F; Varella-Garcia M; Finocchiaro G; Skokan M; Gajapathy S; Carnaghi C; Rimassa L; Rossi E; Ligorio C; Di Tommaso L; Holmes AJ; Toschi L; Tallini G; Destro A; Roncalli M; Santoro A; Jänne PA
Br J Cancer; 2008 Jul; 99(1):83-9. PubMed ID: 18577988
[TBL] [Abstract][Full Text] [Related]
2. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant.
Molinari F; Martin V; Saletti P; De Dosso S; Spitale A; Camponovo A; Bordoni A; Crippa S; Mazzucchelli L; Frattini M
Br J Cancer; 2009 Apr; 100(7):1087-94. PubMed ID: 19293803
[TBL] [Abstract][Full Text] [Related]
3.
van Brummelen EMJ; de Boer A; Beijnen JH; Schellens JHM
Oncologist; 2017 Jul; 22(7):864-872. PubMed ID: 28576857
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer.
Pichler M; Winter E; Stotz M; Eberhard K; Samonigg H; Lax S; Hoefler G
Br J Cancer; 2012 May; 106(11):1826-32. PubMed ID: 22549179
[TBL] [Abstract][Full Text] [Related]
5. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.
Morelli MP; Overman MJ; Dasari A; Kazmi SMA; Mazard T; Vilar E; Morris VK; Lee MS; Herron D; Eng C; Morris J; Kee BK; Janku F; Deaton FL; Garrett C; Maru D; Diehl F; Angenendt P; Kopetz S
Ann Oncol; 2015 Apr; 26(4):731-736. PubMed ID: 25628445
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
Sforza V; Martinelli E; Ciardiello F; Gambardella V; Napolitano S; Martini G; Della Corte C; Cardone C; Ferrara ML; Reginelli A; Liguori G; Belli G; Troiani T
World J Gastroenterol; 2016 Jul; 22(28):6345-61. PubMed ID: 27605871
[TBL] [Abstract][Full Text] [Related]
7. Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas.
Raghav KP; Shetty AV; Kazmi SM; Zhang N; Morris J; Taggart M; Fournier K; Royal R; Mansfield P; Eng C; Wolff RA; Overman MJ
Oncologist; 2013; 18(12):1270-7. PubMed ID: 24149137
[TBL] [Abstract][Full Text] [Related]
8. A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer.
Do K; Cao L; Kang Z; Turkbey B; Lindenberg ML; Larkins E; Holkova B; Steinberg SM; Raffeld M; Peer CJ; Figg WD; Eugeni M; Jacobs P; Choyke P; Wright JJ; Doroshow JH; Kummar S
Clin Colorectal Cancer; 2015 Sep; 14(3):154-61. PubMed ID: 25861837
[TBL] [Abstract][Full Text] [Related]
9. Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.
Lupini L; Bassi C; Mlcochova J; Musa G; Russo M; Vychytilova-Faltejskova P; Svoboda M; Sabbioni S; Nemecek R; Slaby O; Negrini M
BMC Cancer; 2015 Oct; 15():808. PubMed ID: 26508446
[TBL] [Abstract][Full Text] [Related]
10. Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer.
De Stefano A; Carlomagno C
World J Gastroenterol; 2014 Aug; 20(29):9732-43. PubMed ID: 25110411
[TBL] [Abstract][Full Text] [Related]
11. Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer.
Di Fiore F; Sesboüé R; Michel P; Sabourin JC; Frebourg T
Br J Cancer; 2010 Dec; 103(12):1765-72. PubMed ID: 21139621
[TBL] [Abstract][Full Text] [Related]
12. KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings.
Webster J; Kauffman TL; Feigelson HS; Pawloski PA; Onitilo AA; Potosky AL; Cross D; Meier PR; Mirabedi AS; Delate T; Daida Y; Williams AE; Alexander GL; McCarty CA; Honda S; Kushi LH; Goddard KA;
Cancer Epidemiol Biomarkers Prev; 2013 Jan; 22(1):91-101. PubMed ID: 23155138
[TBL] [Abstract][Full Text] [Related]
13. KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice.
Blanke CD; Goldberg RM; Grothey A; Mooney M; Roach N; Saltz LB; Welch JJ; Wood WA; Meropol NJ;
Oncologist; 2011; 16(8):1061-8. PubMed ID: 21737577
[TBL] [Abstract][Full Text] [Related]
14. Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models.
Belli V; Matrone N; Napolitano S; Migliardi G; Cottino F; Bertotti A; Trusolino L; Martinelli E; Morgillo F; Ciardiello D; De Falco V; Giunta EF; Bracale U; Ciardiello F; Troiani T
J Exp Clin Cancer Res; 2019 Jun; 38(1):236. PubMed ID: 31164152
[TBL] [Abstract][Full Text] [Related]
15. KRAS mutant colorectal tumors: past and present.
Brand TM; Wheeler DL
Small GTPases; 2012; 3(1):34-9. PubMed ID: 22714415
[TBL] [Abstract][Full Text] [Related]
16. Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer.
Miyamoto Y; Suyama K; Baba H
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28368335
[TBL] [Abstract][Full Text] [Related]
17. Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation.
Saisana M; Griffin SM; May FE
Oncotarget; 2016 Aug; 7(34):54445-54462. PubMed ID: 27437872
[TBL] [Abstract][Full Text] [Related]
18. Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer.
Knickelbein K; Tong J; Chen D; Wang YJ; Misale S; Bardelli A; Yu J; Zhang L
Oncogene; 2018 Aug; 37(33):4599-4610. PubMed ID: 29755130
[TBL] [Abstract][Full Text] [Related]
19. CCR 20th Anniversary Commentary: RAS as a Biomarker for EGFR--Targeted Therapy for Colorectal Cancer-From Concept to Practice.
Camp ER; Ellis LM
Clin Cancer Res; 2015 Aug; 21(16):3578-80. PubMed ID: 26275951
[TBL] [Abstract][Full Text] [Related]
20. Overcoming the hurdles: surmounting acquired resistance to anti-EGFR therapy in metastatic colorectal cancer.
Sackstein PE; Chintapally N; Wilgucki M; Hartley ML; Alqahtani A; Weinberg BA
Clin Adv Hematol Oncol; 2023 Nov; 21(11):572-583. PubMed ID: 37948593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
